Previous 10 | Next 10 |
NantKwest (NK) and its collaborating partner ImmunityBio have announced to add a third cohort to ongoing Phase 2 immunotherapy trial for locally advanced or metastatic pancreatic cancer, and include patients who have failed all approved standards of care.The therapy includes co...
Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist Anktiva™ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancreatic cancer. ...
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET. The conference pres...
Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, announces the licensing of its next-generation natural killer-based ...
NantKwest (NASDAQ: NK ) inks an agreement with privately held ImmunityBio to develop, manufacture and commercialize vaccines and therapeutics for COVID-19. More news on: NantKwest, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Both companies agree to share equally in costs relating to COVID-19 therapeutics and vaccine candidates globally; global net profits to be shared 60%/40% in favor of the company contributing the product NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeut...
Cord Blood Registry (CBR) by Generate Life Sciences and NantKwest ( NK +6.7% ) announces collaboration for development of COVID-19 treatment leveraging newborn stem cells. More news on: NantKwest, Inc., Healthcare stocks news, Read more ...
LOS ANGELES , and EL SEGUNDO, Calif. , Aug. 10, 2020 /PRNewswire/ -- CBR ® by Generate Life Sciences , the world's largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, today announced a collab...
Though small-cap stocks don't get the attention larger companies do, there are some impressive companies that investors should consider. Here are 5 small cap stocks - INO, OSTK, ACMR, NK and VAPO - that have Buy ratings on our POWR Ratings service. Small-cap stocks receive minimal attention...
The healthcare sector has benefited from the biotech and pharmaceutical industry's efforts to develop COVID-19 therapeutics and vaccines. Most of the big pharma companies have stepped up and led the way with antivirals, antibodies, and are committed to producing millions of doses of their vacc...
News, Short Squeeze, Breakout and More Instantly...
NantKwest Company Name:
NK Stock Symbol:
NASDAQ Market:
Imerys Enters Long-Term Partnership with TotalEnergies for Renewable Power at its Santa Barbara County Facility PR Newswire A TotalEnergies solar and battery storage solution to bring 130-year-old Lompoc industrial site into new era of sustainability and smart energy manag...
Creates Leading Immunotherapy and Cell Therapy Company ImmunityBio , Inc. and NantKwest , Inc. ( NASDAQ: NK ), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditi...
NantKwest, Inc . ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special ...